Here’s why the Atomo (ASX:AT1) share price is soaring 10%

Personal rapid COVID-19 tests are in the news today, and the Atomo share price is benefitting.
The post Here’s why the Atomo (ASX:AT1) share price is soaring 10% appeared first on The Motley Fool Australia. –

The Atomo Diagnostics Ltd (ASX: AT1) share price is soaring today amid calls for the Australian government to approve rapid COVID-19 tests for personal use.

Atomo Diagnostics has partnered with Access Bio to create a rapid COVID-19 test. The test, named CareStart EZ COVID-19 test, has been approved for emergency use in the United States.

Right now, the Atomo Diagnostic share price is up 10%. The medical device company’s shares are trading for 23 cents apiece.

Let’s take a closer look at the news making headlines today.

Push for personal rapid COVID-19 tests

The Atomo Diagnostic share price is gaining amid reports state and federal governments are being lobbied to approve rapid COVID-19 tests for personal use.

According to reporting by, the Victorian Transport Association’s CEO Peter Anderson is pushing for personal rapid tests to be available to allow truck drivers to travel freely between states.

Anderson is also calling for more testing stations to be created on the border between NSW and Victoria.

Currently, truck drivers entering Victoria must receive a COVID-19 test every 3 days despite the results sometimes taking 3 days to be returned.

Additionally, ABC Radio reported this morning that the New South Wales government will soon announce a roadmap for Sydney’s next 4 weeks of lockdown, which may include personal rapid COVID-19 tests.

Numerous publications have reported NSW year 12 students might be among those using personal rapid COVID-19 tests.

However, the Royal College of Pathologists of Australasia has criticised the idea, saying they’re not accurate enough to be useful.

Finally, according to ABC News, Australia’s Health Department stated the tests aren’t useful when there are low rates of COVID-19 circulating.

Market watchers might be particularly excited about the Atomo Diagnostic share price today. That’s because the company’s rapid COVID-19 test has already been approved for use in Australian aged care homes.

Atomo Diagnostics share price snapshot

Despite today’s boost, the Atomo Diagnostic share price is still firmly in the red.

Right now, the Atomo Diagnostics share price is down 29% year to date.

The company has a market capitalisation of around $113 million, with approximately 586 million shares outstanding.

The post Here’s why the Atomo (ASX:AT1) share price is soaring 10% appeared first on The Motley Fool Australia.

Should you invest $1,000 in Atomo Diagnostics right now?

Before you consider Atomo Diagnostics, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Atomo Diagnostics wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

The Afterpay (ASX:APT) share price is down 16% in a month. Here’s why
5 small-cap ASX shares on their way up

Why the Nickel Mines (ASX:NIC) share price is the worst performer on the ASX 200 today
Google (NASDAQ:GOOG) share price climbs on blockbuster earnings
The Venture Minerals (ASX:VMS) share price has slipped today. Here’s why

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!